OTS - Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed
2020. August 27. 11:10
Jena/ Germany, 27 August, 2020 (APA/OTS) - New long-term results
from the international TARGIT-A breast cancer study, based on ZEISS
technology, have been published(1) - Use of targeted
intra-operative radiotherapy (TARGIT), as a single dose - with
ZEISS INTRABEAM - directly after removal of a tumor, confirmed as
non-inferior, when compared with external beam radiotherapy (EBRT).
Within the accuracy of the study, the risk of a local tumor
recurrence in the breast is similar and non-breast cancer death is
reduced. The TARGIT-A randomized, multi-center phase 3 study
involving 2298 patients with a median patient follow-up time of 8.6
years meets the highest scientific standards.
Globally more than 40,000 patients have already been treated,
in over 350 breast cancer centers, with the TARGIT method. "Single
dose intra-operative radiotherapy for early stage breast cancer can
be a better alternative to conventional whole breast radiotherapy
for most patients during primary tumor management " stated the
principal investigator Professor Jayant Vaidya, Professor of
Surgery and Oncology and Scientific Director at University College
London when presenting the results of the study. "These excellent
results provide real clinical justification for single
intraoperative radiation in suitable patients with early breast
cancer. It is now essential to develop the corresponding treatment
guidelines as soon as possible", added Professor Jeffrey Tobias,
Professor of Oncology at University College London and joint
initiator of the TARGIT-A study.
Positive clinical study results validate TARGIT as an option in
breast cancer treatment
The local, recurrence-free survival rate of women treated with
single dose TARGIT is non-inferior when compared with EBRT. The
mortality in the TARGIT arm was even lower because of fewer
cardio-vascular deaths.
"We are delighted with the positive results, as the ZEISS
INTRABEAM 600 now represents an outstanding treatment alternative
for many patients. We are confident that the procedure can now find
its way into everyday clinical practice" said Ludwin Monz, CEO of
Carl Zeiss Meditec AG.
(1) https://www.bmj.com/content/370/bmj.m2836
TARGIT method underscored as an efficiency-oriented treatment
'This study reflects two decades of interdisciplinary clinical
research by leading radiation oncologists, surgeons, physicists and
health economists. The TARGIT-A trial has offered many breast
cancer patients a treatment that is well tolerated, effective,
convenient and highly cost efficient', summarized Professor William
Small, Professor of Radio-oncology at Loyola University, Chicago
and one of the world's leading radiation oncologists.
Contacts for the press:
Petra Rettenmaier
Head of Marketing Communications Visualization
Carl Zeiss Meditec AG
Phone: +49 7364 204-232
Email: press.meditec@zeiss.com
Contact for investors
Sebastian Frericks
Director of Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
Email: investors.meditec@zeiss.com
www.zeiss.de/presse
Brief Profile
Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the
world's leading medical technology companies and is included in the
German MDAX and TecDAX stock indices. The Company supplies
innovative technologies and application-oriented solutions designed
to help doctors improve the quality of life of their patients. The
company offers complete solutions for the diagnosis and treatment
of eye diseases - including implants and consumables. In
microsurgery, the Company provides innovative visualization
solutions. With approximately 3,230 employees worldwide, the
company generated revenue totaling €1,459.3 million in fiscal year
2018/19 (ended 30 September).
The company is headquartered in Jena, Germany. The company has
subsidiaries in Germany and abroad; more than 50 percent of its
employees are based in the US, Japan, Spain and France. The Center
for Application and Research (CARIn) in Bangalore, India and the
Carl Zeiss Innovations Center for Research and Development in
Shanghai, China, strengthen the Company's presence in these rapidly
developing economies. Around 41 percent of Carl Zeiss Meditec AG
shares are in free float. The remaining approx. 59 percent are held
by Carl Zeiss AG, one of the world's leading companies in the
optical and optoelectronic industries.
For more information please visit: www.zeiss.com/med
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.